|
Drug-specific outcomes
|
The absolute number of PIPs per patient of the top five occurring PIP drugs: [11]
|
|
Proton pump inhibitor (PPI) for peptic ulcer disease at full therapeutic dosage for >8 weeks
|
|
Long-term (>3 months) use of NSAIDs for relief of mild joint pain in osteoarthritis
|
|
Long-term (>1 month) use of long-acting benzodiazepines, for example, chlordiazepoxide, flurazepam, nitrazepam, chlorazepate and benzodiazepines with long-acting metabolites for example, diazepam
|
|
Any regular duplicate drug class prescription
|
|
TCAs with an opiate or calcium channel blocker
|
|
Mean number of PIPs per patient of the top five PIP drugs (as above)
|
|
Patient-reported outcomes
|
Health status (EQ-5D)
|
|
Patients’ Beliefs about Medicine Questionnaire (BMQ)
|
|
Well-being Questionnaire (WBQ-12)
|
|
Process-of-care measures
|
Number of GP visits (6 months prior to enrolment and at 4 and 12 month follow-up)
|
|
Number of hospital admissions (6 months prior to enrolment and at 4 and 12 month follow-up
|
|
Process evaluations
|
Decisions made per PIP
|
|
Number of times alternatives were prescribed
|
|
Reported primary reason for decision made for example, risks outweigh benefits, patient preference, hospital/consultant initiated
|
